Concepedia

Laura Vangeel

LV

Statistics

Publications

28

Citations

1.9K

H-Index

18

Active since

2016

Affiliations

KU Leuven(Current)

Rega Institute for Medical Research

Global Virus Network

Scripps (United States)

California Institute for Biomedical Research

Laura Vangeel is an author at KU Leuven specializing in molecular virology, virology, and antiviral pharmacology.

Publications per year

2016–2023

28

Publications

28

Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern

Laura Vangeel, Winston Chiu, Steven De Jonghe et al. · Antiviral Research · 2022 · 433 citations · Full text

Life Sciences, Infectious Diseases, Medicinal Chemistry +17

Ultralarge Virtual Screening Identifies SARS-CoV-2 Main Protease Inhibitors with Broad-Spectrum Activity against Coronaviruses

Andreas Luttens, Hjalmar Gullberg, Eldar Abdurakhmanov et al. · Journal of the American Chemical Society · 2022 · 244 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

The Substitutions L50F, E166A, and L167F in SARS-CoV-2 3CLpro Are Selected by a Protease Inhibitor <i>In Vitro</i> and Confer Resistance To Nirmatrelvir

Dirk Jochmans, Kim Donckers, Antitsa Stoycheva et al. · mBio · 2023 · 170 citations · Full text

Life Sciences, Infectious Diseases, Pharmacology +16

Identification of Inhibitors of SARS-CoV-2 3CL-Pro Enzymatic Activity Using a Small Molecule in Vitro Repurposing Screen

Maria Kuzikov, Elisa Costanzi, Jeanette Reinshagen et al. · ACS Pharmacology & Translational Science · 2021 · 159 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +15

The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model

Rana Abdelnabi, Caroline S. Foo, Suzanne J. F. Kaptein et al. · EBioMedicine · 2021 · 145 citations · Full text

Pharmacy, Infectious Diseases, Infectious Disease Pharmacotherapy +16

1–5 of 28